Bioinformatics analysis of the expression level and clinical significance of prefoldin family in hepatocellular carcinoma

doi:10.3877/cma.j.issn.2095-3232.2023.02.020

Abstract

Abstract:

Objective

To analyze the expression level and prognostic value of prefoldins (PFDs) family in hepatocellular carcinoma (HCC) by bioinformatics approach.

Methods

GEPIA2 database was employed to obtain the mRNA expression data of PFDs family members in HCC and its correlation with clinical staging. The correlation between the expression levels of PFDs family members and tumor grading was analyzed by UALCAN database. Immunohistochemical images of PFDs family members in HCC and normal liver tissues were obtained and compared by HPA database. The effect of PFDs family members expression on the survival of HCC patients was assessed by Kaplan-Meier plotter database. Clinical data of HCC patients were downloaded from TCGA. PFDs family members and related pathological parameters were subjected to multivariate Cox's regression analysis. Enrichment analysis of PFDs family proteins was carried out by DAVID 6.8 bioinformatics tool. The relationship between the expression levels of PFDs family members and immune infiltration of HCC was analyzed by TIMER 2.0 database.

Results

The expression levels of PFDN1, PFDN2, PFDN3 and PFDN4 mRNA and protein in HCC tissues were significantly higher than those in normal liver tissues (P<0.05), which were positively correlated with tumor grading and clinical staging of HCC patients (P<0.05). The survival time of HCC patients with overexpression of PFDN1, PFDN2, PFDN3 and PFDN4 genes was significantly shorter (HR=1.47, 1.45, 1.61, 1.66; P<0.05). PFDN1, PFDN2 and PFDN4 were the independent prognostic factors of HCC patients (HR=1.58, 1.64, 2.04; P<0.05). Gene ontology (GO) and KEGG pathway analyses showed that PFDs family molecules played a role in RNA and mRNA splicing and decomposition, and participated in RNA transport, mRNA monitoring pathway and ribosome synthesis in eukaryotes and other related signaling pathways. The expression of PFDs family members was positively correlated with the expression of helper T cells (Th) 2, CD56⁺NK cells and plasma cell-like dendritic cells in HCC, whereas negatively associated with the expression of Th17, neutrophils and central memory T cells.

Conclusions

High expression of PFDs family members in HCC tissues is correlated with the poor prognosis of HCC patients. The biological function of PFDs is intimately associated with splicer and immune cell infiltration.

Key words: Carcinoma, hepatocellular, Prefoldins, Prognosis, Computational biology

Fuping Li, Mao Wang, Rui Cheng, Shangpeng Li, Yinhai Dai. Bioinformatics analysis of the expression level and clinical significance of prefoldin family in hepatocellular carcinoma[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(02): 227-235.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3232.2023.02.020

https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/Y2023/V12/I02/227

Figures/Tables 8

References 30

[1]	Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021[J]. CA Cancer J Clin, 2021, 71(1):7-33.
[2]	Forner A, Reig M, Bruix J. Hepatocellular carcinoma[J]. Lancet, 2018, 391(10127):1301-1314.
[3]	林国桢, 代天星, 邓铭彬, 等. MTCL1在肝癌中表达及其对术后复发的影响[J/OL]. 中华肝脏外科手术学电子杂志, 2021, 10(6): 622-628.
[4]	Mo SJ, Zhao HC, Tian YZ, et al. The role of prefoldin and its subunits in tumors and their application prospects in nanomedicine[J]. Cancer Manag Res, 2020(12):8847-8856.
[5]	Zhou C, Guo ZY, Xu LQ, et al. PFND1 predicts poor prognosis of gastric cancer and promotes cell metastasis by activating the Wnt/β-catenin pathway[J]. Onco Targets Ther, 2020(13):3177-3186.
[6]	Peñate X, Praena-Fernández JM, Romero Pareja P, et al. Overexpression of canonical prefoldin associates with the risk of mortality and metastasis in non-small cell lung cancer[J]. Cancers, 2020, 12(4):1052.
[7]	Wang D, Shi W, Tang Y, et al. Prefoldin 1 promotes EMT and lung cancer progression by suppressing cyclin A expression[J]. Oncogene, 2017, 36(7):885-898.
[8]	Wang P, Zhao J, Yang X, et al. PFDN1, an indicator for colorectal cancer prognosis, enhances tumor cell proliferation and motility through cytoskeletal reorganization[J]. Med Oncol, 2015, 32(12):264.
[9]	Nami B, Wang Z. Genetics and expression profile of the tubulin gene superfamily in breast cancer subtypes and its relation to taxane resistance[J]. Cancers, 2018, 10(8):274.
[10]	Al-Yhya N, Khan MF, Almeer RS, et al. Pharmacological inhibition of HDAC1/3-interacting proteins induced morphological changes, and hindered the cell proliferation and migration of hepatocellular carcinoma cells[J]. Environ Sci Pollut Res Int, 2021, 28(35):49000-49013.
[11]	Tang Z, Li C, Kang B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses[J]. Nucleic Acids Res, 2017, 45(W1):W98-102.
[12]	Chandrashekar DS, Bashel B, Balasubramanya SAH, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses[J]. Neoplasia, 2017, 19(8):649-658.
[13]	Uhlén M, Fagerberg L, Hallström BM, et al. Proteomics. tissue-based map of the human proteome[J]. Science, 2015, 347(6220):1260419.
[14]	Nagy Á, Munkácsy G, Győrffy B. Pancancer survival analysis of cancer hallmark genes[J]. Sci Rep, 2021, 11(1):6047.
[15]	Tomczak K, Czerwińska P, Wiznerowicz M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge[J]. Contemp Oncol, 2015, 19(1A):A68-77.
[16]	Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources[J]. Nat Protoc, 2009, 4(1):44-57.
[17]	Li T, Fu J, Zeng Z, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells[J]. Nucleic Acids Res, 2020, 48(W1):W509-514.
[18]	Chang KW, Yang PY, Lai HY, et al. Identification of a novel actin isoform in hepatocellular carcinoma[J]. Hepatol Res, 2006, 36(1):33-39.
[19]	Kim SY, Kim JC, Kim JK, et al. Hepatitis B virus X protein enhances NFkappaB activity through cooperating with VBP1[J]. BMB Rep, 2008, 41(2):158-163.
[20]	Collins C, Volik S, Kowbel D, et al. Comprehensive genome sequence analysis of a breast cancer amplicon[J]. Genome Res, 2001, 11(6):1034-1042.
[21]	Miyoshi N, Ishii H, Mimori K, et al. Abnormal expression of PFDN4 in colorectal cancer: a novel marker for prognosis[J]. Ann Surg Oncol, 2010, 17(11):3030-3036.
[22]	Takano M, Tashiro E, Kitamura A, et al. Prefoldin prevents aggregation of α-synuclein[J]. Brain Res, 2014(1542):186-194.
[23]	Tashiro E, Zako T, Muto H, et al. Prefoldin protects neuronal cells from polyglutamine toxicity by preventing aggregation formation[J]. J Biol Chem, 2013, 288(27):19958-19972.
[24]	Tao Y, Han Y, Yu L, et al. The predicted key molecules, functions, and pathways that bridge mild cognitive impairment (MCI) and Alzheimer's disease (AD)[J]. Front Neurol, 2020(11):233.
[25]	Dehghan-Nayeri N, Rezaei-Tavirani M, Omrani MD, et al. Identification of potential predictive markers of dexamethasone resistance in childhood acute lymphoblastic leukemia[J]. J Cell Commun Signal, 2017, 11(2):137-145.
[26]	Garnelo M, Tan A, Her Z, et al. Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma[J]. Gut, 2017, 66(2):342-351.
[27]	Fu J, Xu D, Liu Z, et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients[J]. Gastroenterology, 2007, 132(7):2328-2339.
[28]	Xiao N, Li K, Zhu X, et al. CD74(+) macrophages are associated with favorable prognosis and immune contexture in hepatocellular carcinoma[J]. Cancer Immunol Immunother, 2022, 71(1):57-69.
[29]	Cai XY, Gao Q, Qiu SJ, et al. Dendritic cell infiltration and prognosis of human hepatocellular carcinoma[J]. J Cancer Res Clin Oncol, 2006, 132(5):293-301.
[30]	Yang H, Beutler B, Zhang D. Emerging roles of spliceosome in cancer and immunity[J]. Protein Cell, 2022, 13(8):559-579.

临床病理特征	例数	单因素分析		多因素分析
临床病理特征	例数	HR（95%CI）	P	HR（95%CI）	P
年龄	373	1.31（1.19~1.78）	0.35	1.21（0.85~1.71）	0.30
T分期	370	2.13（1.47~3.03）	0.53	0.45（0.06~3.31）	0.43
N分期	370	2.03（0.50~8.28）	0.32	0.56（0.08~4.18）	0.59
M分期	272	4.08（1.28~12.97）	0.18	2.87（0.89~9.20）	0.08
病理分期	349	2.09（1.43~3.06）	0.00	5.35（0.71~40.25）	0.10
PFDN1（高表达）	370	1.45（1.03~2.06）	0.03	1.58（1.02~2.45）	0.04
PFDN2（高表达）	370	1.46（1.03~2.07）	0.03	1.64（1.06~2.55）	0.03
PFDN3（高表达）	370	1.28（0.90~1.80）	0.02	1.27（0.90~1.80）	0.18
PFDN4（高表达）	370	1.79（1.26~2.54）	0.00	2.04（1.30~3.19）	0.00
PFDN5（高表达）	370	1.60（1.13~2.27）	0.06	1.58（1.18~2.24）	0.07
PFDN6（高表达）	370	1.18（0.84~1.66）	0.35	1.16（0.83~1.64）	0.39

临床病理特征	例数	单因素分析		多因素分析
临床病理特征	例数	HR（95%CI）	P	HR（95%CI）	P
年龄	373	1.31（1.19~1.78）	0.35	1.21（0.85~1.71）	0.30
T分期	370	2.13（1.47~3.03）	0.53	0.45（0.06~3.31）	0.43
N分期	370	2.03（0.50~8.28）	0.32	0.56（0.08~4.18）	0.59
M分期	272	4.08（1.28~12.97）	0.18	2.87（0.89~9.20）	0.08
病理分期	349	2.09（1.43~3.06）	0.00	5.35（0.71~40.25）	0.10
PFDN1（高表达）	370	1.45（1.03~2.06）	0.03	1.58（1.02~2.45）	0.04
PFDN2（高表达）	370	1.46（1.03~2.07）	0.03	1.64（1.06~2.55）	0.03
PFDN3（高表达）	370	1.28（0.90~1.80）	0.02	1.27（0.90~1.80）	0.18
PFDN4（高表达）	370	1.79（1.26~2.54）	0.00	2.04（1.30~3.19）	0.00
PFDN5（高表达）	370	1.60（1.13~2.27）	0.06	1.58（1.18~2.24）	0.07
PFDN6（高表达）	370	1.18（0.84~1.66）	0.35	1.16（0.83~1.64）	0.39

Please choose a citation manager

Content to export